HUTCHMED (HCM)
NASDAQ:HCM
Want to see HCM full AI Analyst Report?
HCM Stock Chart & Stats
$15.74
$0.15(1.02%)
At close: 4:00 PM EST
$15.74
$0.15(1.02%)
Day’s Range― - ―
52-Week Range$11.10 - $19.50
Previous CloseN/A
Volume23.53K
Average Volume (3M)48.41K
Market Cap
$2.04B
Enterprise Value$2.04B
Total Cash (Recent Filing)$1.36B
Total Debt (Recent Filing)$100.73M
Price to Earnings (P/E)52.5
Beta0.36
Next Earnings
Aug 03, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.77
Shares Outstanding174,467,030
10 Day Avg. Volume34,563
30 Day Avg. Volume48,412
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.85
Price to Sales (P/S)4.16
P/FCF Ratio-28.96
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue3.38
Enterprise Value/Gross Profit37.88
Enterprise Value/Ebitda-271.90
Forecast
1Y Price Target
$16.80Price Target Upside6.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.32
Revenue Forecast (FY)$639.22M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage gives the company durable financial flexibility to fund clinical programs, absorb trial delays, and pursue partnerships or milestone-driven transactions without immediate refinancing pressure. This conservatism supports longer-term R&D and commercialization plans.
Diversified Revenue ModelA multi-pronged revenue model (self-commercialized sales, partner milestones/royalties, and licensing) reduces dependence on any single product or market. Structurally, this smooths cash flow volatility across development cycles and provides alternative funding as pipeline assets mature.
Reasonable Gross MarginA ~38.7% gross margin indicates underlying product-level profitability and pricing power versus peers. That margin provides a structural buffer to support SG&A and continued R&D investment even when operating profitability fluctuates, helping sustain commercialization efforts.
Bears Say
Weak Cash GenerationMaterial negative operating and free cash flow are durable concerns: persistent cash burn forces reliance on external financing, asset sales, or partner funding. Over a multi-month horizon this constrains the firm's ability to self-fund trials and maintain commercial momentum without dilutive or restrictive financing.
Revenue Decline And VolatilityA recent revenue decline and choppy growth history reduce predictability for cash flows and investment planning. Over 2–6 months this undermines confidence in scaling commercial operations and makes milestone-based revenue less reliable as a stable funding source for ongoing clinical programs.
Poor Earnings QualityExceptional net income driven by non-operating items while EBIT and EBITDA are negative signals low earnings quality. Such one-off gains are not durable, complicate forecasting, and can mask operational weaknesses that matter for long-term capital allocation and sustainable profitability.
HUTCHMED News
HCM FAQ
What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $11.10 and its highest was $19.50 in the past 12 months.
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $2.04B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Aug 03, 2026 which is in 61 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Mar 05, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.5 by -$2.49.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 0.11.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $0.01 in its last earnings report, missing expectations of $2.5. Following the earnings report the stock price went up 1.502%.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in HCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HUTCHMED Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.80 (6.73% Upside)
$16.80 (6.73% Upside)
Hedge Fund Trend
Decreased
By 110.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
37.04%
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
HUTCHMED
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.
HCM Company Deck
HCM Earnings Call
Q4 2026
0:00 / 0:00
HCM Stock 12 Month Forecast
Average Price Target
$16.80
▲(6.73% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
0.07% Mutual Funds
0.44% Other Institutional Investors
99.38% Public Companies and
Individual Investors